Inogen Announces Release to Market of the Inogen At Home(TM), an Innovative Home Oxygen Concentrator

GOLETA, Calif., Oct. 21, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that it has released to market its innovative home oxygen concentrator called the Inogen At Home™.

The Inogen At Home is the lightest five liter per minute continuous flow oxygen concentrator on the market today. At approximately 18 pounds, the Inogen At Home is more than 10 to 20 pounds lighter than current oxygen concentrators from leading manufacturers with equivalent flow capacity. Additionally, the Inogen At Home has low power consumption, which should reduce the cost of electricity for oxygen therapy patients.

"Inogen is proud to release the Inogen At Home to the market this week and we believe we have created a home concentrator with product attributes that will be patient preferred," said Raymond Huggenberger, CEO.

Inogen's release of the Inogen At Home, combined with their award winning Inogen One family of products, positions the Company with a complete product portfolio able to fulfill the clinical requirements of most oxygen therapy patients. While the Inogen One product line is clinically validated for 24/7 use, the Inogen At Home gives Inogen a compelling solution for nocturnal-only oxygen therapy patients that do not yet require a portable solution, which are estimated to represent 30% of total oxygen patients in the United States.

The Inogen At Home was released for purchase by oxygen therapy patients this week. More information on the product including how to purchase can be found on Inogen's website at www.inogen.com.

Inogen has used, and intends to continue to use, its Investor Relations website, www.inogen.com/investor, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit www.inogen.com/investor.

Use of Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Inogen's new products, its plans, objectives, expectations and/or strategies relating to such new products and the field of at home oxygen equipment. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including challenges inherent in developing, manufacturing, and launching new products.  Information on these and additional risks, uncertainties, and other information affecting Inogen's business and operating results are contained in Inogen's Annual Report on Form 10-K for the year ended December 31, 2013 and in Inogen's subsequent reports on Form 10-Q and Form 8-K. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.

About Inogen

Inogen is innovation in oxygen therapy. We are a medical technology company that develops, manufactures and markets innovative oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. www.inogen.com

CONTACT: Investor Relations Contact:
         ir@inogen.net
         805-562-0500 ext 7

         Media Contact:
         Byron Myers
         805-562-0503

Released October 21, 2014